Regulation of mTOR function in response to hypoxia by REDD1 and the tumor suppressor complex TSC1/TSC2 - Review of the evidence
The study shows that, in cells subjected to low oxygen, REDD1 activates the TSC1/TSC2 brake and reduces mTORC1 activity, limiting protein synthesis signals. Independent experiments confirm this circuit in some cell models, but hepatic studies show alternative pathways. Evidence in humans remains limited, contextual, and not yet robust.
- Published 17/11/2026
- Updated 17/11/2026
- Article history
ABSTRACT
The analyzed publication investigated how cells reduce mTOR activity when oxygen is scarce. The authors observed that this response requires REDD1, a hypoxia-induced gene, and the TSC1/TSC2 complex, a system that acts as a brake on cell growth. When REDD1 or TSC1/TSC2 were altered, the ability of hypoxia to reduce signals controlled by mTOR decreased.
In the context of "The Choice to Live in Health or Illness" by Dr. A. Colonnese and R. Panzironi, the study contributes primarily to the narrative that REDD1 links stress from low oxygen availability to the TSC1/TSC2 complex and the reduction of mTORC1 activity. Subsequent studies confirm this axis in cells and fibroblasts, clarifying mechanisms involving TSC2, AKT, and the PP2A protein. However, other research shows that in the liver, hypoxia can inhibit mTORC1 even without REDD1 and TSC1/TSC2. The relationship is therefore well-supported as a cellular mechanism, but it is not universal across tissues nor proven as a general clinical explanation for insulin resistance.
Analyzed study
Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex
DOI: 10.1101/gad.1256804
PMID: 15545625
PMCID: PMC534650
The research question was how hypoxia, i.e., a reduced availability of oxygen, manages to slow down mTOR, a protein that coordinates protein synthesis and cell growth. The hypothesis evaluated was that this response did not depend solely on energy scarcity, but required REDD1 and the TSC1/TSC2 complex. This complex can be described as a molecular brake: when active, it reduces the signal that leads to the activation of mTORC1.
The relevance to paragraphs 4.10 and 21.9 is direct: the research covered by the article documents the segment hypoxia → increase in REDD1 → dependence on TSC1/TSC2 → reduction in mTORC1 activity. Regarding paragraph 4.6, however, it supports the general role of mTOR as an integrator of stress and growth signals, but it does not directly study mTORC2 nor does it demonstrate that mTORC2 phosphorylates AKT. The study cannot prove that this circuit causes insulin resistance in humans, nor that every form of cellular stress necessarily utilizes REDD1.
Materials and methods of the original study
The available material consists only of the abstract. The study used cellular experiments in which hypoxia was simulated, comparing cells with a functional TSC1/TSC2 complex to cells lacking TSC1 or TSC2. The expression of REDD1 and the activity of several proteins involved in the response to energy availability, including AMPK and LKB1, were also experimentally altered.
mTOR activity was assessed through the phosphorylation of S6K and 4E-BP1. Phosphorylation is the addition of a small chemical group to a protein, which often modifies its activity; in this case, a reduction in the phosphorylation of S6K and 4E-BP1 was used as an indicator of lower mTORC1 activity. The authors also evaluated cell proliferation under hypoxic conditions. The number of experiments, the cell lines used, the duration of hypoxia, the oxygen percentage, exclusion criteria, details of statistical analyses, and complete numerical values are not reported in the available material.
Results
The main finding is that hypoxia reduced mTOR activity only when both REDD1 and the TSC1/TSC2 complex were present. The loss of TSC1 or TSC2 blocked the inhibitory effect of hypoxia on the S6K and 4E-BP1 targets. Simply put, without this braking system, the cell continued to maintain higher activity in signals normally associated with protein production and growth.
Disrupting REDD1 also prevented the reduction in mTOR activity caused by hypoxia. Conversely, experimentally increasing REDD1 was sufficient to decrease S6K phosphorylation, but only if TSC1/TSC2 was functional. This data places REDD1 upstream of the TSC1/TSC2 complex in the observed response.
The authors also reported that, under hypoxic conditions, TSC2-deficient cells maintained abnormally high proliferation. They also observed an abnormal accumulation of the hypoxia-inducible factor, HIF, when the TSC1/TSC2 complex was inactive. The study distinguished this pathway from the response to energy depletion: the hypoxia-induced inhibition of mTOR did not require AMPK or LKB1. The abstract does not report percentages, P-values, confidence intervals, or effect sizes; therefore, such data are not available for quantitative assessment.
Interpretation
For a cell receiving little oxygen, continuing to grow and produce proteins can increase resource consumption. The results indicate that REDD1 helps activate an adaptive brake, TSC1/TSC2, which reduces mTORC1 activity. This is the scientifically documented step that explains why the publication was cited in the sections dedicated to the REDD1–TSC1/TSC2–mTOR relationship.
However, this result does not equate to proving that REDD1 directly "activates" TSC1/TSC2 through physical contact. The study shows a functional dependency: without TSC1/TSC2, REDD1 cannot reduce the signal measured on S6K. Subsequent research has proposed more detailed mechanisms, including the modulation of the interaction between TSC2 and 14-3-3 proteins or the reduction of AKT activation.
The publication does not directly demonstrate that REDD1 causes persistent metabolic dysfunction, muscle loss, or clinical insulin resistance. Furthermore, it does not analyze mTORC2. Its contribution to the book's narrative primarily concerns mTORC1 and cellular adaptation to hypoxia.
Independent supporting evidence
Close experimental confirmation comes from DeYoung and colleagues, who studied mouse embryonic fibroblasts, U2OS cells, and mouse models. Under hypoxia, REDD1 promoted the dissociation of TSC2 from 14-3-3 proteins, which are regulatory proteins that can hold other proteins in a less active configuration. The loss of REDD1 prevented both this dissociation and the reduction of S6K1 phosphorylation. Experimental increases in REDD1 also countered insulin-induced mTORC1 activation. This directly confirms the passage in the book stating that REDD1 promotes the action of the TSC1/TSC2 complex and reduces mTORC1, but this evidence remains primarily cellular and animal-based [1].
A second study outlined a possible alternative or complementary pathway. Dennis and colleagues used mouse embryonic fibroblasts lacking REDD1 and a cell line with inducible REDD1. REDD1 increased the association of the phosphatase PP2A with AKT and reduced AKT phosphorylation at the Thr308 site. Since AKT normally inactivates TSC2 through phosphorylation, the reduction of AKT favored a greater inhibitory effect exerted by TSC2 on mTORC1. The result supports the direction described in the book—REDD1 leading to lower mTORC1 activity—but specifies that the connection may also involve the modulation of AKT and not just a single mechanism acting on TSC2 [2].
These findings converge on the main biological significance: when REDD1 increases under specific stress conditions, the mTORC1 signals that support protein synthesis and cell growth decrease. However, the available data do not allow for the automatic transfer of this sequence to all human tissues or for it to be considered a proven cause of clinical insulin resistance.
Conflicting evidence
Evidence directly relevant to the mechanism has been identified, which limits its generalizability. Wolff and colleagues compared mouse fibroblasts, thymocytes, and primary liver cells subjected to hypoxia. In fibroblasts and thymocytes, the loss of REDD1 compromised the hypoxia-induced reduction of mTORC1, consistent with the original study. In hepatocytes, however, hypoxia continued to inhibit mTORC1 even in the absence of REDD1 or TSC1/TSC2.
In liver cells, the response was found to be more dependent on LKB1, AMPK, and raptor, a component of the mTORC1 complex. This observation does not contradict the REDD1–TSC1/TSC2 circuit in the models where it has been demonstrated, but it shows that hypoxia can utilize different pathways depending on the cell type. Consequently, it is incorrect to present REDD1 as the sole universal switch for mTORC1 in every tissue [3].
Summary table of evidence
The table distinguishes the publication subject to the review from independent research that confirms or delimits its significance.
| Reference | Study type | Population or model | Main result | Direction of evidence | Strength of evidence |
|---|---|---|---|---|---|
| Original study | Experimental cellular | Cells with alterations in REDD1, TSC1, or TSC2; details not reported in the available abstract | Hypoxia requires REDD1 and TSC1/TSC2 to reduce S6K and 4E-BP1 signals associated with mTORC1 | direct confirmation | moderate |
| [1] | Experimental cellular and animal | Mouse embryonic fibroblasts, U2OS cells, and mouse model | REDD1 promotes TSC2/14-3-3 dissociation and reduces S6K1 phosphorylation in response to hypoxia | direct confirmation | moderate |
| [2] | Experimental cellular | REDD1-deficient mouse embryonic fibroblasts and inducible REDD1 cell line | REDD1 promotes AKT dephosphorylation by PP2A, reducing signaling to mTORC1 | indirect confirmation | moderate |
| [3] | Experimental cellular and animal | Mouse fibroblasts, thymocytes, and primary hepatocytes | In hepatocytes, hypoxia inhibits mTORC1 even without REDD1 and TSC1/TSC2 | discordant evidence | moderate |
Confirmation of the evidence
Claim in the book
In sections 4.10 and 21.9 of “The Choice to Live in Health or Illness” by Dr. A. Colonnese and R. Panzironi, the central claim is that REDD1 translates stress signals, particularly hypoxia, into a reduction of mTOR activity through the TSC1/TSC2 complex. Section 4.6 also places mTOR within the broader framework of the integration of nutrient, energy, and hormonal signals.
Hypoxia → REDD1 → modulation of TSC1/TSC2 → reduction of mTORC1 → decreased phosphorylation of S6K and 4E-BP1 → reduction of protein synthesis and growth signals
The publication subject to the Evidence Review was used in the book to support the following passage: under hypoxic conditions, the induction of REDD1 requires the TSC1/TSC2 complex to inhibit mTORC1 and reduce the phosphorylation of its targets associated with protein synthesis.
The correspondence is specific and biologically consistent. The analyzed study demonstrates that the loss of REDD1 or TSC1/TSC2 prevents the normal reduction of mTOR signals in hypoxia. DeYoung and colleagues later confirmed that REDD1 is necessary to modify the regulation of TSC2 and to reduce mTORC1 during hypoxia [1]. Dennis and colleagues provided a further mechanistic explanation: REDD1 can decrease AKT activation, removing from TSC2 a portion of the inhibitory signal exerted by growth factors [2].
However, this chain should not be interpreted as identical in every organ. In liver cells, hypoxia can reduce mTORC1 through LKB1, AMPK, and raptor without requiring REDD1 or TSC1/TSC2 [3]. Independent literature therefore confirms the circuit described in the book as a contextual cellular response to hypoxic stress, but limits the idea that it represents the only control pathway for mTOR or a complete clinical explanation of insulin resistance.
Overall level of confirmation
MECHANISTIC CONFIRMATION
The REDD1–TSC1/TSC2–mTORC1 pathway is supported by multiple independent experiments involving genetic and biochemical perturbations. However, most of the evidence derives from cells and animal models, while relevant research shows a clear dependence on cell type. Direct demonstration in humans and on clinical metabolic outcomes remains limited.
Conclusions
The analyzed study directly supports the fact that, in specific cell models subjected to hypoxia, REDD1 and the TSC1/TSC2 complex are necessary to reduce mTORC1 activity. This is the scientific core for which the publication is relevant to the sections of the book dedicated to REDD1 and mTOR.
Independent research confirms that REDD1 can reduce mTORC1 signaling through the regulation of TSC2 and AKT. The framework is well-supported at a mechanistic level. However, it remains necessary to distinguish acute cellular adaptation to hypoxia from chronic clinical consequences: the mechanism is not universal across tissues and does not, by itself, prove that REDD1 causes insulin resistance in humans.
Overall assessment
The REDD1–TSC1/TSC2–mTORC1 narrative is mechanistically confirmed and quite well-supported in cellular and animal models. The consistency with the book's sections is high regarding hypoxia and the reduction of growth signals. However, tissue dependency requires caution when extending the model to human metabolic physiology.
References
[1] Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling
[2] REDD1 enhances protein phosphatase 2A–mediated dephosphorylation of Akt to repress mTORC1 signaling
[3] Cell-Type-Dependent Regulation of mTORC1 by REDD1 and the Tumor Suppressors TSC1/TSC2 and LKB1 in Response to Hypoxia
Editorial note
Artificial Intelligence was used solely as a tool to support editorial and documentary work. All content, interpretations, bibliographic citations and conclusions have been verified, reviewed and approved by the author, who assumes full scientific responsibility for them.
The manuscript was also subject to independent peer review prior to publication.
To ensure maximum transparency, the article's complete history — including the dates of submission, review, acceptance and publication, as well as information on the peer review process — is available on the dedicated Article History page.